On May 4, 2023 PharmaMar (MSE:PHM) reported the recruitment of the first patient in a new Phase I clinical trial for the treatment of patients with different types of solid tumors with its new molecule of marine origin: PM54 (Press release, PharmaMar, MAY 4, 2023, View Source [SID1234631045]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is the first-in-human (FIH) clinical trial with this new compound that is being carried out in hospitals in Spain, other European countries and the United States. This clinical trial aims to find the recommended dose of the treatment.

This new molecule has been tested in the laboratory, both in cell cultures, in vitro, and in vivo. In both cases, PharmaMar’s new compound showed promising anti-tumor activity in a wide variety of tumor types. PM54 is the second PharmaMar compound to enter into the clinical development stage in the last few months after PM534, which FIH phase I trial was initiated in December 2022.